Anavex Life Sciences submits Nasdaq compliance plan

Rhea-AI Filing Summary

Anavex Life Sciences Corp. reports that on July 20, 2026 it submitted a Compliance Plan to the Listing Qualifications Department of The Nasdaq Stock Market to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC.

The company previously received a deficiency notification letter on May 20, 2026 because it did not timely file its Form 10-Q for the quarter ended March 31, 2026. The notice has no immediate effect on the listing of its common stock, which continues to trade on The Nasdaq Global Select Market under the symbol AVXL. Nasdaq staff is reviewing the Compliance Plan and may grant an extension if it is accepted; if not, the company can request a hearing before an independent Hearings Panel.

Positive

• None.

Negative

• Nasdaq deficiency for late 10-Q: Anavex Life Sciences is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to timely file its Form 10-Q for the quarter ended March 31, 2026, creating potential Nasdaq listing risk if compliance is not restored.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Terms

Nasdaq Listing Rule 5250(c)(1), deficiency notification letter, Compliance Plan, Hearings Panel

4 terms

Nasdaq Listing Rule 5250(c)(1) regulatory

"to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

deficiency notification letter regulatory

"the Company received a deficiency notification letter (the “Notice”) from the Nasdaq Staff"

Compliance Plan regulatory

"timely submitted its plan (the “Compliance Plan”) to the Listing Qualifications Department"

A compliance plan is a company's documented roadmap of rules, procedures and checks designed to ensure it follows laws, industry rules and internal policies. Think of it as an instruction manual and regular checklist that helps prevent costly mistakes, fines or business disruptions by flagging problems early and guiding corrective action. Investors watch these plans because a clear, enforced plan lowers legal and reputational risk and indicates stronger management and governance.

Hearings Panel regulatory

"request a hearing on the Nasdaq Staff’s determination before an independent Hearings Panel"

A hearings panel is a review body at a stock exchange that hears the case when the exchange has decided a company no longer qualifies to keep its shares listed. The company presents a plan to regain compliance, and the panel decides whether the listing continues, on what conditions, and for how long. The decision can keep a stock trading or end its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Anavex Life Sciences (AVXL) receive a Nasdaq deficiency notice?

Anavex Life Sciences received a Nasdaq deficiency notification because it did not timely file its Form 10-Q for the quarter ended March 31, 2026, putting it out of compliance with Nasdaq Listing Rule 5250(c)(1) requiring timely periodic SEC reports.

What action has Anavex Life Sciences (AVXL) taken to address the Nasdaq non-compliance?

Anavex Life Sciences has submitted a Compliance Plan to Nasdaq on July 20, 2026. This plan is under review by Nasdaq staff and is intended to outline how the company will regain compliance with Listing Rule 5250(c)(1) regarding timely SEC filings.

Does the Nasdaq deficiency notice affect AVXL’s current stock listing status?

The deficiency notice has no immediate effect on Anavex Life Sciences’ listing. Its common stock continues to trade on The Nasdaq Global Select Market under the symbol AVXL while Nasdaq staff reviews the Compliance Plan submitted by the company.

What happens if Nasdaq does not accept AVXL’s Compliance Plan?

If Nasdaq does not accept the Compliance Plan, Anavex Life Sciences will have an opportunity to request a hearing before an independent Hearings Panel, where it can present its case for regaining compliance with Nasdaq Listing Rule 5250(c)(1).

Which specific Nasdaq rule is Anavex Life Sciences (AVXL) out of compliance with?

Anavex Life Sciences is out of compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires listed companies to timely file all required periodic financial reports with the SEC, including Forms 10-Q and 10-K for their reporting periods.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 08:59 AM EDT Learn about SEC filing dates

false 0001314052 0001314052 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 20, 2026

ANAVEX LIFE SCIENCES CORP.

(Exact name of Registrant as Specified in Its Charter)

Nevada			001-37606	98-0608404
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
630 5th Avenue, 20th Floor New York, NY USA				10111
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 1-844-689-3939

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AVXL		Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On July 20, 2026, Anavex Life Sciences Corp. (the “Company”) timely submitted its plan (the “Compliance Plan”) to the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“Rule 5250(c)(1)”). As previously disclosed, on May 20, 2026, the Company received a deficiency notification letter (the “Notice”) from the Nasdaq Staff indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, it is not in compliance with Rule 5250(c)(1).

The Notice has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Global Select Market under the symbol “AVXL”.

The Compliance Plan is currently under review by the Nasdaq Staff. If the Compliance Plan is accepted by the Nasdaq Staff, the Nasdaq Staff may grant an extension for the Company to regain compliance. If the Compliance Plan is not accepted by the Nasdaq Staff, the Company will have an opportunity to request a hearing on the Nasdaq Staff’s determination before an independent Hearings Panel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ANAVEX LIFE SCIENCES CORP.
Date:	July 20, 2026	By:	/s/ Sandra Boenisch
			Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB